Matching-adjusted indirect comparison (MAIC) of brexucabtagene autoleucel (brexu-cel) and pirtobrutinib in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) previously treated with a covalent bruton tyrosine kinase inhibitor (cBTKI)

3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel as First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma

Economic Burden Associated with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Nationwide Health Insurance Claims Database Study in Japan During 2012-2022

Real World Data of Axicabtagene Ciloleucel as Second Line Therapy for Patients with Large B Cell Lymphoma: First Results of a LYSA Study from the French DESCAR-T Registry

Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events After Brexucabtagene Autoleucel Treatment in Patients With Relapsed or Refractory Mantle Cell Lymphoma in ZUMA-2

Real-World Outcomes of Brexucabtagene Autoleucel for Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukemia: Evidence From The CIBMTR Registry

Cost-Effectiveness of Axicabtagene Ciloleucel Versus Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma in the US

A Retrospective Intrapatient Analysis From ZUMA-5: Axicabtagene Ciloleucel (Axi-Cel) Compared With Prior Standard-of-Care Therapy in Patients With Relapsed/Refractory Follicular Lymphoma

Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-Up From the Phase 2 ZUMA-5 Trial

Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): an Exploratory Long-Term Survival Assessment in Patients With Refractory Large B-Cell Lymphoma From ZUMA-1

Pre- and post-treatment immune contexture correlates with long term response in large B cell lymphoma patients treated with Axicabtagene ciloleucel (axi-cel)

Improved Overall Survival With Axicabtagene Ciloleucel vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Real-World Outcomes of Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma: A CIBMTR Subgroup Analysis of High-Risk Characteristics

Comparative Effectiveness of Axicabtagene Ciloleucel Versus Historical Standard of Care in Patients With Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

An Updated Comparison of Clinical Outcomes From 4-Year Follow-Up of ZUMA-5 (Axicabtagene Ciloleucel) and the International SCHOLAR-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma

Physician Treatment Preferences in Relapsed/Refractory Follicular Lymphoma: A Discrete Choice Experiment

Outcomes of Patients with Relapsed/Refractory Mantle Cell Lymphoma Treated with Brexucabtagene Autoleucel in ZUMA-2 and ZUMA-18, an Expanded Access Study

Phase 1 Study Of CART-ddBCMA For The Treatment Of Patients With Relapsed And/Or Refractory Multiple Myeloma: Results From At Least 1-year Follow-up In All Patients

Real-World Evidence in the United States on the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma